Scholarlink

Background <p>Renal impairment is a recognized complication of transcatheter aortic valve implantation (TAVI), impacting morbidity and mortality. Understanding its incidence, predictors, and prognostic implications is essential to optimizing patient outcomes.</p> Purpose <p>To determine the incidence, predictors, and prognostic significance of renal impairment in patients undergoing TAVI.</p> Methods <p>This prospective observational study was conducted on 147 patients, with 144 completing the study. Patients with severe symptomatic aortic stenosis (aortic valve area (AVA) &lt; 1&#xa0;cm²) were included. Clinical, echocardiographic, and procedural parameters were analyzed to identify predictors of post-TAVI renal impairment, defined per Valve Academic Research Consortium (VARC)-2 AKIN criteria.</p> Results <p>Renal impairment occurred in 13.9% of patients post-TAVI. Compared to those without impairment, affected patients more frequently underwent ad-hoc revascularization (90% vs. 21.3%, <i>P</i> &lt; 0.001), received higher contrast volume (median 200 mL vs. 130 mL, <i>P</i> &lt; 0.001), and had longer procedures (82.5 ± 29 vs. 60.9 ± 28.3&#xa0;min, <i>P</i> = 0.002). They also exhibited lower post-procedural ejection fraction (EF) (47.4% ± 9.7% vs. 59.8% ± 9.7%, <i>P</i> &lt; 0.001) and higher incidence of regional wall motion abnormalities (60% vs. 12.3%, <i>P</i> &lt; 0.001). Multivariate analysis identified ad-hoc revascularization (OR = 448.7, 95% CI: 17.09–11778.5, <i>P</i> &lt; 0.001), lower EF (OR = 0.87, 95% CI: 0.79–0.97, <i>P</i> = 0.009), and contrast volume (OR = 0.98, 95% CI: 0.96–1.00, <i>P</i> = 0.045) as independent predictors.</p> Conclusions <p>Renal impairment post-TAVI is multifactorial, with contrast volume, ad hoc revascularization, and reduced EF as key independent predictors. Minimizing contrast use and optimizing procedural strategies may mitigate renal risk and improve patient outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Renal impairment in transcatheter aortic valve implantation: incidence, predictors, and prognostic significance

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月18日

查看全文
  • Abdelrahman Ahmed Abdelrahman,
  • Mahmoud Baraka,
  • Nabil Farag,
  • Ahmed E. Mostafa,
  • Diaa Kamal

摘要

Background

Renal impairment is a recognized complication of transcatheter aortic valve implantation (TAVI), impacting morbidity and mortality. Understanding its incidence, predictors, and prognostic implications is essential to optimizing patient outcomes.

Purpose

To determine the incidence, predictors, and prognostic significance of renal impairment in patients undergoing TAVI.

Methods

This prospective observational study was conducted on 147 patients, with 144 completing the study. Patients with severe symptomatic aortic stenosis (aortic valve area (AVA) < 1 cm²) were included. Clinical, echocardiographic, and procedural parameters were analyzed to identify predictors of post-TAVI renal impairment, defined per Valve Academic Research Consortium (VARC)-2 AKIN criteria.

Results

Renal impairment occurred in 13.9% of patients post-TAVI. Compared to those without impairment, affected patients more frequently underwent ad-hoc revascularization (90% vs. 21.3%, P < 0.001), received higher contrast volume (median 200 mL vs. 130 mL, P < 0.001), and had longer procedures (82.5 ± 29 vs. 60.9 ± 28.3 min, P = 0.002). They also exhibited lower post-procedural ejection fraction (EF) (47.4% ± 9.7% vs. 59.8% ± 9.7%, P < 0.001) and higher incidence of regional wall motion abnormalities (60% vs. 12.3%, P < 0.001). Multivariate analysis identified ad-hoc revascularization (OR = 448.7, 95% CI: 17.09–11778.5, P < 0.001), lower EF (OR = 0.87, 95% CI: 0.79–0.97, P = 0.009), and contrast volume (OR = 0.98, 95% CI: 0.96–1.00, P = 0.045) as independent predictors.

Conclusions

Renal impairment post-TAVI is multifactorial, with contrast volume, ad hoc revascularization, and reduced EF as key independent predictors. Minimizing contrast use and optimizing procedural strategies may mitigate renal risk and improve patient outcomes.